ALLMedicine™ Primary CNS Lymphoma Center
Research & Reviews 282 results
https://clinicaltrials.gov/ct2/show/NCT05389423
Jun 24th, 2022 - Background: Non-Hodgkin lymphoma (NHL) is the most common cancer among people living with HIV (PLWH) in the United States. Even in the modern era of antiretroviral therapy (ART), PLWH have an 11- to 17-fold higher risk of NHL than the general popu...
https://clinicaltrials.gov/ct2/show/NCT03964090
Jun 24th, 2022 - Background: Aggressive B-cell lymphomas with secondary involvement of the CNS (sCNSL) have a grave prognosis No standard of care exists for sCNSL; treatment approaches include combination chemotherapy regimens effective in primary CNS lymphoma (PC...
https://clinicaltrials.gov/ct2/show/NCT02203526
Jun 24th, 2022 - Background: Primary CNS lymphoma (PCNSL) is a rare subtype of diffuse large B-cell lymphoma The outcome for patients with this diagnosis is significantly worse than for that of systemic DLBCL. Most treatment approaches in the past have included hi...
https://doi.org/10.1007/s11060-022-04062-z 10.1182/blood.2020008377 10.1093/neuonc/nox187 10.1016/j.hoc.2021.09.004 10.3390/cancers13205061 10.1111/ejh.13639 10.1016/S1470-2045(18)30356-5 10.1007/s11060-019-03257-1 10.1111/ajco.13427 10.3892/ijo.2021.5180 10.6004/jnccn.2020.7667 10.1016/j.clml.2020.10.015 10.1212/WNL.0000000000000314 10.18632/oncotarget.8370 10.1002/ajh.23812 10.1111/jcmm.12252 10.1016/S1040-8428(03)00120-3 10.18632/oncotarget.15899 10.1200/JCO.2003.09.139 10.1016/S1470-2045(10)70229-1 10.1016/S1470-2045(18)30747-2 10.1016/S2352-3026(16)00036-3 10.1016/S0140-6736(09)61416-1 10.1016/S2352-3026(15)00074-5 10.1007/s00277-021-04745-z 10.1097/NRL.0000000000000328 10.5045/br.2020.S010 10.3390/cancers13122934 10.1111/bjh.15661 10.1186/s40364-021-00282-z 10.2147/CMAR.S322467
Journal of Neuro-oncology; Li Q, Ma Y et. al.
Jun 23rd, 2022 - High-dose methotrexate (HD-MTX)-based chemotherapy regimen is the first-line option for primary central nervous system lymphoma (PCNSL). This prospective cohort study aimed to evaluate the efficacy and adverse effects of HD-MTX plus idarubicin (ID...
https://doi.org/10.1016/j.clml.2022.05.007
Clinical Lymphoma, Myeloma & Leukemia; Samhouri Y, Mustafa Ali MK et. al.
Jun 16th, 2022 - The best consolidation strategy after induction chemotherapy in Primary CNS Lymphoma (PCNSL) remains controversial. Our objective is to estimate the overall survival (OS) for autologous stem cell transplantation (ASCT) versus whole brain radiation...
Clinicaltrials.gov 47 results
https://clinicaltrials.gov/ct2/show/NCT05389423
Jun 24th, 2022 - Background: Non-Hodgkin lymphoma (NHL) is the most common cancer among people living with HIV (PLWH) in the United States. Even in the modern era of antiretroviral therapy (ART), PLWH have an 11- to 17-fold higher risk of NHL than the general popu...
https://clinicaltrials.gov/ct2/show/NCT03964090
Jun 24th, 2022 - Background: Aggressive B-cell lymphomas with secondary involvement of the CNS (sCNSL) have a grave prognosis No standard of care exists for sCNSL; treatment approaches include combination chemotherapy regimens effective in primary CNS lymphoma (PC...
https://clinicaltrials.gov/ct2/show/NCT02203526
Jun 24th, 2022 - Background: Primary CNS lymphoma (PCNSL) is a rare subtype of diffuse large B-cell lymphoma The outcome for patients with this diagnosis is significantly worse than for that of systemic DLBCL. Most treatment approaches in the past have included hi...
https://clinicaltrials.gov/ct2/show/NCT04443829
Jun 14th, 2022 - The CAROUSEL Trial is a single-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in adults (age ≥16) with relapsed/refractory Primary CNS Lymphoma. The ATIMP for this study i...
https://clinicaltrials.gov/ct2/show/NCT04022980
Jun 13th, 2022 - This is a 2-stage phase 1B study of nivolumab consolidation following completion of HD-MTX containing induction chemotherapy in older (≥ 65 years old) patients with previously untreated primary CNS lymphoma. Stage 1 is designed to evaluate the saf...
News 18 results
https://www.onclive.com/view/car-t-cell-therapy-demonstrates-efficacy-without-increased-risk-of-crs-or-icans-in-cns-involved-lbcl
Apr 25th, 2022 - The CAR T-cell therapies axicabtagene ciloleucel (axi-cel; Yescarta), tisagenlecleucel (Kymriah), and lisocabtagene maraleucel (liso-cel; Breyanzi) evoked responses without increased risk of cytokine release syndrome (CRS) or immune effector cell–...
https://www.medscape.com/viewarticle/964469
Dec 9th, 2021 - Key Takeaway Sarcopenia measured by temporalis muscle thickness (TMT) robustly and independently predicts early relapse and short survival in primary central nervous system (CNS) lymphoma. Very thin TMT is a better predictor of mortality than the ...
https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-cft7455-for-multiple-myeloma
Aug 17th, 2021 - The FDA has granted an orphan drug designation to CFT7455, a MonoDAC degrader targeting IKZF1/3, for use as a potential therapeutic option in patients with multiple myeloma, according to an announcement from C4 Therapeutics, Inc.1 We are pleased ...
https://www.medpagetoday.com/hematologyoncology/lymphoma/92452
May 6th, 2021 - Two commonly used thiotepa-based conditioning regimens were associated with favorable outcomes among patients with primary central nervous system lymphoma (PCNSL) undergoing autologous hematopoietic cell transplant (AHCT), according to a retrospec...
https://www.onclive.com/view/adding-rituximab-and-thiotepa-to-chemo-doublet-improves-outcomes-in-primary-cns-lymphoma
Dec 20th, 2020 - AndreÌs Ferreri, MD The MATRIX regimen, comprised of a methotrexate/cytarabine backbone plus thiotepa and rituximab, improved outcomes in patients with primary CNS lymphoma, according to results from the international randomized phase II ELSG #3...
